FY2024 Earnings Estimate for InflaRx Issued By HC Wainwright

InflaRx (NASDAQ:IFRX) – Equities research analysts at HC Wainwright decreased their FY2024 earnings estimates for InflaRx in a research note issued on Monday, November 11th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.05) per share for the year, down from their previous forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.13) EPS.

InflaRx Stock Down 3.9 %

InflaRx stock opened at $1.95 on Thursday. The company’s 50-day moving average price is $1.54 and its two-hundred day moving average price is $1.52. The stock has a market cap of $114.82 million, a P/E ratio of -1.81 and a beta of 1.57. InflaRx has a twelve month low of $1.16 and a twelve month high of $2.44.

Hedge Funds Weigh In On InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC raised its position in InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the quarter. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. 42.39% of the stock is currently owned by institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.